Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPAL: Lansoprazole in Idiopathic Pulmonary Fibrosis
NCT04965298Phase 3Recruiting
- Sponsor
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Start
- Jun 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of lansoprazole in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Norfolk and Norwich University Hospitals NHS Foundation Trust. Primary endpoint: Absolute change in percent predicted forced vital capacity at 12 months. Started Jun 2021; status: recruiting.
02
Drugs
lansoprazole
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04965298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965298.